Experimental studies suggest that proprotein convertase subtilisin/kexin type 9 (PCSK9) is an important regulator of LDL metabolism because of its ability to facilitate degradation of the LDL receptor. We investigated the association between plasma PCSK9 concentration and LDL apolipoprotein B-100 (apo B-100) metabolism in men with a wide range of body mass index values.
Epidemiologic and clinical studies have consistently demonstrated that an increased plasma concentration of apolipoprotein B-100 (apo B-100), 5 the major protein component of LDL, is associated with an increased risk of cardiovascular disease (1 ) . Apo B-100 is essential for the binding of LDL particles to the LDL receptor (LDLR) for cellular uptake and degradation (2 ) . Circulating LDL apo B-100 is a function of the hepatic secretion of VLDL, conversion of VLDL to LDL, and, to a greater extent, clearance of LDL particles by the liver via the LDLR. Individuals with familial hypercholesterolemia, combined hyperlipidemia, and/or the metabolic syndrome are characterized by increased plasma apo B-100, chiefly due to reduced catabolism of LDL apo B-100 (3) (4) (5) .
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is an important regulator of the LDLR and hence of LDL metabolism (6 ) . It is a secreted protease produced mostly by the liver and is detectable in human plasma. Gain-of-function mutations of PCSK9 are associated with autosomal dominant hypercholesterolemia (7 ), whereas PCSK9 deficiency leads to low LDL cholesterol concentrations and protection against cardiovascular disease (8 ) . In vitro and animal studies have demonstrated that circulating PCSK9 binds to the LDLR and subsequently targets it for lysosomal degradation (6, 9 ) . We hypothesized that increased plasma PCSK9 concentrations in humans are associated with decreased LDL catabolism. To test this hypothesis, we used a stable-isotopic method and examined the correlation between plasma PCSK9 concentration and the kinetics of LDL apo B-100.
We recruited 21 nonsmoking men with a body mass index between 20 and 35 kg/m 2 . None of the men had diabetes mellitus, the apo E2/E2 or E4/E4 genotype, macroproteinuria, increased serum creatinine (Ͼ120 mol/L), hypothyroidism, increased serum liver enzymes, or consumption of Ͼ30 g alcohol per day. None reported a history of cardiovascular disease or taking agents affecting lipid metabolism. All study participants provided written consent as approved by the Ethics Committee of the Royal Perth Hospital and South Eastern Sydney Area Health Service. This clinical protocol has been described previously (4, 5 ) . In brief, an infusion of deuterated leucine was administered intravenously, and 9 mL EDTA-anticoagulated whole blood was collected at baseline and at various times after isotope injection (5, 10, 20, 30 , and 40 min, and 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, and 10 h). Additional fasting blood samples were collected in the morning on the following 4 days of the same week. Blood cells were separated immediately (1000g for 15 min at 4°C), and the plasma was stored at 4°C until the end of the week (day 5). Diets were assessed for energy and major nutrients.
On day 5, apo B-100 in the LDL fraction was separated by sequential ultracentrifugation, precipitated by isopropanol, delipidated, and hydrolyzed, as previously described (4, 5 ) . GC-MS with selected ion monitoring of derivatized samples was used to assess isotopic enrichment. Tracer/tracee ratios were determined for each sample. The SAAM II program (SAAM Institute, Seattle, WA) was used to fit the model to the observed tracer/tracee ratios. The fractional catabolic rate (FCR) of LDL apo B-100 was derived from the model parameters giving the best fit. The production rates of LDL apo B-100 were the product of the corresponding FCR and the pool size and were expressed in milligrams per kilogram per day. The pool size was calculated as the product of the corresponding apo B-100 concentration (in milligrams per liter) and plasma volume (0.045 L/kg).
Plasma aliquots were combined to yield 5 pooled LDL samples per study participant (5 ) . apo B-100 was isolated from each lipoprotein fraction with isopropanol and quantified by the Lowry method. Samples of nonanticoagulated blood (4 mL) and EDTAanticoagulated blood (4 mL) were collected on day 1 of the kinetic study before isotope infusion. After centrifugation within 1 h (1000g for 15 min at 4°C), the serum or the EDTA-treated plasma was removed and sent for routine biochemistry analysis. In brief, serum lipids and glucose concentrations were measured by enzymatic methods. Plasma insulin was measured by RIA (DiaSorin). The homeostasis model assessment (HOMA) score was used to estimate insulin resistance. Plasma lathosterol concentration was assayed by GC-MS. The ELISA protocol has previously been described in detail (10 ) . Because discrepant absolute PCSK9 concentrations have been reported in the literature, likely owing to the variable ability of the antibodies used to recognize epitopes on recombinant and endogenous PCSK9 (10 -13 ), we modified our ELISA protocol by using a recombinant PCSK9 standard that does not contain the V5 epitope. This new reference was obtained with stably transfected HEK293 cells producing the 692-residue wild-type human PCSK9 sequence fused to a histidine tag (a generous gift from GlaxoSmithKline, Les Ulis, France). We purified the secreted PCSK9 protein from cell-conditioned medium by immobilized-nickel affinity chromatography (10 ) . The purity of the recombinant PCSK9 preparation was Ͼ98% by SDS-PAGE followed by silver staining. With this PCSK9 reference, the ELISA was linear (r 2 ϭ 0.98) between 0 g/L and 250 g/L PCSK9. The inter-and intraplate CVs were 6.5% and 4.5%, respectively. PCSK9 concentrations in aliquots of plasma from a compound-heterozygote individual lacking PCSK9 (generously provided by Jay Horton, Department of Molecular Genetics, University of Texas Southwestern Medical Center, Dallas, TX) were measured and found to be less than our detection threshold of 2 g/L. All statistical analyses were carried out with SPSS 15 (SPSS). Data were expressed as the mean (SD). Associations were examined by simple and multivariate linear regression methods. Statistical significance was defined at the 5% level with a 2-tailed test (i.e., P Ͻ 0.05). Table 1 summarizes the anthropometric and biochemical characteristics of the 21 study participants. They were middle-aged and normotensive. Eleven had the metabolic syndrome according to National Cholesterol Education Program Adult Treatment Panel III criteria (14 ) . The PCSK9 and LDL apo B-100 kinetic data were comparable to those of other studies (5 ). Mean daily energy and nutrient intake values were as follows: 7731 (1505) kJ, 31% (6%) energy from fat, 46% (8%) energy from carbohydrates, 19% (4%) energy from protein, and 4% (6%) energy from alcohol. Individual LDL apo B-100 kinetic data are shown in In the univariate analysis, the plasma PCSK9 concentration was significantly and positively correlated with the concentrations of total cholesterol (r ϭ 0.543; P ϭ 0.011), LDL cholesterol (r ϭ 0.543; P ϭ 0.011), and apo B-100 (r ϭ 0.548; P ϭ 0.010), and with the LDL apo B-100 pool size (r ϭ 0.514; P ϭ 0.023). The plasma PCSK9 concentration was also inversely correlated with the LDL apo B-100 FCR (r ϭ Ϫ0.456; P ϭ 0.038) (Fig. 1) . This correlation was stronger among participants with metabolic syndrome (r ϭ Ϫ0.660; P ϭ 0.027); however, plasma PCSK9 concentration was not significantly associated with plasma insulin (r ϭ Ϫ0.346; P ϭ 0.125), HOMA score (r ϭ Ϫ0.313; P ϭ 0.167), plasma lathosterol concentration (r ϭ 0.288; P ϭ 0.206), or LDL apo B-100 production rate (r ϭ Ϫ0.174; P ϭ 0.450). Plasma lathosterol concentration was significantly and inversely correlated with the LDL apo B-100 FCR (r ϭ Ϫ0.473; P ϭ 0.030) but not with the LDL apo B-100 production rate (r ϭ Ϫ0.201; P ϭ 0.382).
The association between the plasma PCSK9 concentration and the LDL apo B-100 FCR remained significant after adjusting for age (r ϭ Ϫ0.450; P ϭ 0.046), obesity status (r ϭ Ϫ0.457; P ϭ 0.043), insulin (r ϭ Ϫ0.505; P ϭ 0.023), HOMA score (r ϭ Ϫ0.494; P ϭ 0.027), and energy intake (r ϭ Ϫ0.508; P ϭ 0.022). This association was not significant after adjusting for plasma lathosterol concentration (r ϭ Ϫ0.418; P ϭ 0.067).
We have presented new evidence showing that plasma PCSK9 concentration is positively correlated with the LDL apo B-100 pool size and that this finding is related to the former's significant inverse correlation with the LDL apo B-100 FCR. This effect of PCSK9 is independent of age, obesity status, insulin resistance, and energy intake. Previous studies have examined the association between plasma PCSK9 and lipid concentrations in healthy, hypercholesterolemic, and type 2 diabetic individuals (10 -13 ) . One study reported that 2 individuals carrying the Ser127Arg mutation in PCSK9 have a 30% decrease in the LDL apo B-100 FCR, but plasma PCSK9 concentrations were not measured in that study (15 ) . We now provide a kinetic basis for the association between plasma PCSK9 concentration and total, LDL cholesterol, and apo B-100 concentrations. The mechanism for the effect of PCSK9 on LDL apo B-100 catabolism involves binding of PCSK9 to the LDLR and subsequent targeting of this receptor for intracellular degradation (6, 9 ) . This mechanism is consistent with our finding that the plasma PCSK9 concentration was significantly and inversely correlated with the LDL apo B-100 FCR. It is noteworthy that a previous report found no correlation in women between the plasma PCSK9 concentration and total and LDL cholesterol concentrations (11 ) . Whether our findings also apply to women merits investigation.
We found that the plasma lathosterol concentration was inversely correlated with the LDL apo B-100 FCR, a result consistent with the central role of cholesterol synthesis in regulating LDLR activity. That the association between the plasma PCSK9 concentration and the LDL apo B-100 FCR was not independent of the plasma lathosterol concentration also agrees with the concomitant regulation of PCSK9, the LDLR, and major cholesterol biosynthetic enzymes at the level of gene expression, notably via the transcription factor sterol-regulatory element binding protein 2 (16, 17 ) and with the role of hepatic cholesterol synthesis in regulating LDLR activity (18 ) . The absence of a correlation between the lathosterol concentration and the apo B production rate agrees with studies showing that triglyceride availability, and not cholesterol synthesis, primarily regulates the production and secretion of apo B-containing lipoprotein (19 ) . Whether this result also applies to individuals with familial hypercholesterolemia merits investigation, given that cholesterol synthesis may be the primary driver of apo B secretion in this phenotype. Our study implies that the FCR of LDL apo B-100 is determined chiefly by variation in LDLR activity; however, this hypothesis needs further investigation with in vivo data of LDLR activity and binding capacity.
Our present data demonstrate that in men with a wide range of body mass index values, the plasma PCSK9 concentration is correlated with LDL apo B catabolism. This observation sheds new light on the pos- 
